Abstract
The causative agent of mumps is a single-stranded, non-segmented, negative sense RNA virus belonging to the Paramyxoviridae family. Besides the classic symptom of painfully swollen parotid salivary glands (parotitis) in mumps virus (MuV)-infected men, orchitis is the most common form of extra-salivary gland inflammation. Mumps orchitis frequently occurs in young adult men, and leads to pain and swelling of the testis. The administration of MuV vaccines in children has been proven highly effective in reducing the incidence of mumps. However, a recent global outbreak of mumps and the high rate of orchitis have recently been considered as threats to male fertility. The pathogenesis of mumps orchitis remains largely unclear due to lack of systematic clinical data analysis and animal models studies. The alarming increase in the incidence of mumps orchitis and the high risk of the male fertility have thus become a major health concern. Recent studies have revealed the mechanisms by which MuV-host cells interact and MuV infection induces inflammatory responses in testicular cells. In this mini-review, we highlight advances in our knowledge of the clinical aspects and possible mechanisms of mumps orchitis.
Introduction
Mumps is a worldwide contagious disease caused by mumsp virus (MuV). MuV is mainly transmitted via the respiratory route. MuV infection results in painful inflammatory symptoms, such as parotitis, orchitis, oophoritis, aseptic meningitis, encephalitis and pancreatitis (). Besides the typical painfully swollen parotitis in infected males, orchitis is the most common extra-salivary inflammation and an important etiological factor of male infertility ().
Mumps orchitis generally manifests around a week after the onset of parotitis (, ). Approximately 30% of mumps orchitis in post pubertal males suffer from infertility or subfertility (). Mumps orchitis may lead to the atrophy of germinal epithelium with spermatogenesis arrest and the disruption of steroidogenesis. MuV complications are not lethal, therefore lacking human samples to examine disease pathogenesis.
Current information on pathogenesis after MuV infection is largely based on investigation using animal models (–). We have recently examined mechanisms underlying MuV infection of testicular cells, MuV-induced immune responses and impairment of testicular functions in mouse models, which provide novel insights into the pathology of mumps orchitis and related male infertility (–). In this mini review, we briefly summarize MuV biology and focus on mechanisms underlying pathogenesis of mumps orchitis.
MuV and Complications
MuV belongs to the Paramyxoviridae family, which consists of enveloped particles that contain a non-segmented single negative-strand RNA genome (Figure 1). The MuV genome consists 15,384 nucleotides that encodes seven proteins: nucleoprotein (NP), polymerase (L), phosphoprotein (P), matrix protein (M), hemagglutinin/neuraminidase (HN), fusion protein (F), and small hydrophobic protein (SH) (). MuV strains can be classified into 12 genotypes based on the nucleotide diversity of the SH gene (, ). Viral RNA encapsulated by NP is the template for replication. A complex of L and P acts as a replicase to transform the negative-strand RNA to a positive-strand RNA and as a transcriptase to generate mRNA. HN and F glycoproteins cooperatively mediate virus attachment and internalization to host cells via its receptor sialic acid that is present on the surface of most mammalian cell types.
Figure 1
MuV is initially transmitted via the respiratory route by the inhalation of contaminated droplets from an infected respiratory tract. Based on the array of symptoms, MuV would initially replicate within the lymphoid and reticuloendothelial tissue of the respiratory tract, which then lead to a transient viremia that may spread viruses into multiple organs (). While it is assumed that MuV first infects the respiratory epithelium, the primary target cells for early infection and replication remain unclear. However, MuV has rarely been detected in blood, probably due to the coincident development of specific antibodies.
Besides asymptomatic and mild respiratory diseases in approximately 30% of infections, the typical characteristics of mumps include swollen parotitis, which is used to diagnose the disease. Parotid gland swelling is mostly bilateral, occurs 2−3 weeks after transmission, and lasts for 2−3 days. The symptom may persist for a week or more in minor cases. Following parotitis, MuV infection can lead to inflammation in the reproductive and central nerve systems, including orchitis, oophoritis, encephalitis, and meningitis (). MuV may also result in myocarditis, pancreatitis and nephritis. While the complications are mostly self-limiting, long-term sequelae such as infertility, paralysis, hydrocephalus and deafness can occur. Mumps orchitis is the most concerned extra-parotid gland inflammation due to its detrimental effect on human reproduction.
Clinical Aspects of Mumps Orchitis
Vaccination and Incidences of Mumps Orchitis
In the pre-vaccine era, mumps was an infectious disease that was most commonly transmitted among children and was mainly complicated with parotitis (, ). With routine MuV vaccination, mumps incidence has dramatically declined. However, there have been large outbreaks of mumps worldwide in the past decades, including vaccinated populations (–). In China, the mumps vaccine was first introduced in the National Immunization Program in 2007 (). From June 2020, the policy had changed to receive two doses of trivalentmeasles, mumps and rubella (MMR) vaccine. The annual occurrence of mumps cases from 2009 to 2019 is shown in Figure 2. After high vaccination coverage, mumps incidence dropped by half in 2016 from its peak in 2012. Notably, mumps incidences slightly increased from 2017 to 2019. This may be due to the fact that more than 10 years have passed since the first one dose vaccine was administered, and vaccine effectiveness has declined.
Figure 2
The recent resurgence of mumps mainly involved adolescents and young adults, with high rates of orchitis frequently reported (, –). Orchitis is the most common complication of mumps and occurs in as high as 40% of all mumps cases in young adult men (). Mumps orchitis is mostly unilateral, but can occur bilaterally in 10−30% of cases (). Unvaccinated postpubertal males are susceptible to virus outbreaks and are at high risk of developing mumps orchitis. In China, the vaccination rate of men born in the 1990s, who are now 30 years old, is low due to lacking MMR vaccination program in less developed areas. Thus, it is essential to be aware of this epidemiological shift and the resurgence of mumps orchitis in the clinic. Cases of orchitis following MMR vaccination are reported in post-pubertal adults, suggesting that the MMR vaccination may have an adverse effect on the testis in certain young adults (–). Therefore, whether unvaccinated male in this age group should be offered the MMR vaccine requires in-depth and carefully evaluation.
Clinical Manifestations
Mumps orchitis usually occurs at about one week after the onset of parotitis in young adult males with MuV infection. The onset of orchitis is associated with constitutional symptoms, such as headache and fever and later manifests as testicular swollen and pain. Examination of the scrotum generally indicates swelling testes, associated tenderness, and inflammation of the scrotum. Epididymitis also occurs in most of the mumps orchitis cases and results in mumps epididymo-orchitis (, ). A recent study demonstrates that the epididymal head is mostly involved in mumps epididymo-orchitis, which is in contrast to bacterial epididymitis that commonly occurs in the cauda epididymis (, ). During the acute phase, the endocrine function of the testes is altered, e.g., decreased testosterone levels. Some cases also show increased luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels (). The acute symptoms can resolve within two weeks; however, testicular atrophy can occur in half of the orchitis patients and is characterized by an oblong shape, low echogenicity, and decreased vascularity based on ultrasonographic findings (, ). However, seminal abnormalities, including sperm count, motility and morphology, may sustain for years after recovery (), suggesting the abnormal spermatogenesis can occur.
Diagnostic and Therapeutic Approaches
There is no standard criteria procedure for MuV diagnosis because it is not a common condition that is observed in hospital. Diagnosis of MuV is mainly based on clinical complication and laboratory testing. Orchitis characteristically presents with swollen and pain testes. Ultrasonography can provide image features, including low echogenicity, hypervascularity, and increased volume of the testes and epididymis (, ). Testicular inflammation and hydrocele could also be detected. The routine urine analysis is necessary for diagnosing the mumps orchitis to rule out bacterial infection ().
The definitive diagnosis of mumps orchitis should be based on laboratory tests. The presence of MuV in saliva or seminal fluid can be determined by real time RT-PCR. The MuV-specific IgM and IgG antibodies in blood can be measured by ELISA for serological markers of MuV infection. A positive serum IgM or a four-fold increase in IgG level is considered serologically positive for MuV infection (). While MuV can be isolated from the seminal fluid within two weeks after symptom onset (), the test for viral infectivity is usually not performed in the clinical diagnosis due to the complicated procedure for this test.
MuV infection is mostly self-limiting, and there is currently no specific antiviral therapy available. The treatment for mumps orchitis generally includes supportive procedures, including bed rest, scrotal support, and analgesic and anti-inflammatory drugs against pain and fever. Symptoms can resolve with treatment in 4−10 days (). Steroid drugs were used to diminish testicular pain and swelling, but it does not alter the clinical course and prevent subsequent atrophy. Interferon has been used in a series of cases to cure mumps orchitis; however, this is a controversial method because there is conflicting evidence on its therapeutic effect. Erpenbach et al. claimed to have prevented testicular damage and infertility in four patients who had bilateral mumps orchitis by using systematic interferon for seven days (). However, Yeniyol et al. found that interferon is not effective in preventing testicular atrophy because 40% of patients presents evidence of total atrophy of seminiferous tubules on testicular biopsies performed during follow-up (). A recent study that assessed a series of 56 cases of mumps orchitis treated with interferon also showed some kind of hormone or sperm impairment in most patients during the later follow up period, while only two patients (14%) were considered free of sequelae (). Although some treatments can diminish the complications of acute mumps orchitis, the preventive and therapeutic approaches of the orchitis-caused testicular damage and subfertility/infertility require establishment.
Mechanisms of Mumps Orchitis
It is difficult to study the pathogenesis of mumps orchitis in humans due to the lack of samples. Recent studies using mouse models provide insights to mechanisms by which MuV infects testicular cells and impairs testicular functions (Figure 3).
Figure 3
MuV Receptors and Testis Tropism
It is well-known that MuV has high tropism to the testis (
Other types of cell receptors such as AXL and MER, which are members of a subfamily of receptor tyrosine kinases, have been suggested as potential candidates for MuV tropism. AXL and MER are abundantly expressed in SCs and LCs and play important roles in regulating testicular immune privilege (
MuV-Induced Immune Response in Testicular Cells
Due to the lack of testicular biopsy from mumps orchitis patients, it is difficult to investigate MuV infection and pathogenesis in the testis. Although humans are believed to be the only natural reservoir, MuV was experimentally used to infect various animal models to evaluate protective immunity against MuV (
To understand the mechanisms underlying MuV-induced orchitis, a recent study investigated the pattern recognition receptors-initiated innate immune responses of testicular cells to MuV infection (
Usually, viral replication in infected cells is restricted by cellular innate antiviral responses. The production of IFNs is a universal mechanism of the host’s defense against viral infection (
Notably, viral infection in male GCs may be sexually transmitted to female partners and fetus, thus leading to virus parallel and vertical transmission (
MuV Infection Damages Testis Function
The cytokines induced by viral infection can mediate organ dysfunction and tissue damage (
The deleterious effects of MuV infection on male GCs have also been examined in a recent study (
Laboratory animal models are critical for the studies on the pathogenesis of MuV-induced diseases. Unfortunately, mice are not susceptible to MuV infection. Although MuV efficiently replicates in mouse testicular cells in vitro, this is not evident in vivo (
Conclusions
The recent outbreaks occurring in highly vaccinated populations have sparked renewed interest in mumps and complications, particularly orchitis. There is a growing concern that a group of mumps cases has shifted from children to young adults and is associated with a high rate of orchitis and severe reproductive problems. The mechanisms behind the development of mumps and orchitis are unknown. Several recent studies on MuV based on primary cells have improved our understanding of mumps virus pathogenesis with regard to MuV receptors-testicular cells interaction, innate immune responses to MuV infection, and detrimental effects on testicular function using mouse models. However, a number of knowledge gaps remain. MuV can effectively replicate in mouse testicular cells in vitro. The testis is an immunoprivileged organ for the protection of the spermatozoon from adverse immune response (
Funding
This work was supported by grants from the National Key R&D program of China (Nos. 2018YFC1003900 and 2016YFA0101001), and the National Natural Science Foundation of China (Nos. 81701430 and 82071633).
Statements
Author contributions
DH and HW designed the concept and wrote the manuscript. DT and FW collected materials and prepared figures. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
HviidARubinSMühlemannK. Mumps. Lancet (2008) 371:932–44. doi: 10.1016/s0140-6736(08)60419-5
2
MasaraniMWazaitHDinneenM. Mumps orchitis. J R Soc Med (2006) 99:573–5. doi: 10.1258/jrsm.99.11.573
3
Ternavasio-de la VegaHGBoronatMOjedaAGarcia-DelgadoYAngel-MorenoACarranza-RodriguezCet al. Mumps orchitis in the post-vaccine era (1967-2009): a single-center series of 67 patients and review of clinical outcome and trends. Med (Baltimore) (2010) 89:96–116. doi: 10.1097/MD.0b013e3181d63191
4
RozinaEEHilgenfeldtM. Comparative study on the neurovirulence of different vaccine strains of parotitis virus in monkeys. Acta Virol (1985) 29:225–30.
5
McCarthyMJubeltBFayDBJohnsonRT. Comparative studies of five strains of mumps virus in vitro and in neonatal hamsters: evaluation of growth, cytopathogenicity, and neurovirulence. J Med Virol (1980) 5:1–15. doi: 10.1002/jmv.1890050102
6
KilhamLMargolisG. Induction of congenital hydrocephalus in hamsters with attenuated and natural strains of mumps virus. J Infect Dis (1975) 132:462–6. doi: 10.1093/infdis/132.4.462
7
ParkerLGillilandSMMinorPSchepelmannS. Assessment of the ferret as an in vivo model for mumps virus infection. J Gen Virol (2013) 94:1200–5. doi: 10.1099/vir.0.052449-0
8
XuPHuangZGaoXMichelFJHirschGHoganRJet al. Infection of mice, ferrets, and rhesus macaques with a clinical mumps virus isolate. J Virol (2013) 87:8158–68. doi: 10.1128/JVI.01028-13
9
WuHZhaoXWangFJiangQShiLGongMet al. Mouse Testicular Cell Type-Specific Antiviral Response against Mumps Virus Replication. Front Immunol (2017) 8:117. doi: 10.3389/fimmu.2017.00117
10
JiangQWangFShiLZhaoXGongMLiuWet al. C-X-C motif chemokine ligand 10 produced by mouse Sertoli cells in response to mumps virus infection induces male germ cell apoptosis. Cell Death Dis (2017) 8:e3146. doi: 10.1038/cddis.2017.560
11
WuHShiLWangQChengLZhaoXChenQet al. Mumps virus-induced innate immune responses in mouse Sertoli and Leydig cells. Sci Rep (2016) 6:19507. doi: 10.1038/srep19507
12
RubinSEckhausMRennickLJBamfordCGDuprexWP. Molecular biology, pathogenesis and pathology of mumps virus. J Pathol (2015) 235:242–52. doi: 10.1002/path.4445
13
JinLOrvellCMyersRRotaPANakayamaTForcicDet al. Genomic diversity of mumps virus and global distribution of the 12 genotypes. Rev Med Virol (2015) 25:85–101. doi: 10.1002/rmv.1819
14
JohanssonBTecleTOrvellC. Proposed criteria for classification of new genotypes of mumps virus. Scand J Infect Dis (2002) 34:355–7. doi: 10.1080/00365540110080043
15
GalazkaAMRobertsonSEKraigherA. Mumps and mumps vaccine: a global review. Bull World Health Organ (1999) 77:3–14. doi: 10.1007/bf02727158
16
EdmundsWJGayNJKretzschmarMPebodyRGWachmannH. Network EPES-e. The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies. Epidemiol Infect (2000) 125:635–50. doi: 10.1017/s0950268800004672
17
VandermeulenCRoelantsMVermoereMRoseeuwKGoubauPHoppenbrouwersK. Outbreak of mumps in a vaccinated child population: a question of vaccine failure? Vaccine (2004) 22:2713–6. doi: 10.1016/j.vaccine.2004.02.001
18
WestphalDWEastwoodALevyADaviesJHuppatzCGillesMet al. A protracted mumps outbreak in Western Australia despite high vaccine coverage: a population-based surveillance study. Lancet Infect Diseases (2019) 19:177–84. doi: 10.1016/s1473-3099(18)30498-5
19
QinWWangYYangTXuXKMengXMZhaoCJet al. Outbreak of mumps in a student population with high vaccination coverage in China: time for two-dose vaccination. Hum Vaccin Immunother (2019) 15:2106–11. doi: 10.1080/21645515.2019.1581526
20
MaRLuLZhouTPanJChenMPangX. Mumps disease in Beijing in the era of two-dose vaccination policy, 2005-2016. Vaccine (2018) 36:2589–95. doi: 10.1016/j.vaccine.2018.03.074
21
BeleniAIBorgmannS. Mumps in the Vaccination Age: Global Epidemiology and the Situation in Germany. Int J Environ Res Public Health (2018) 15:1618. doi: 10.3390/ijerph15081618
22
WillocksLJGuerendiainDAustinHIMorrisonKECameronRLTempletonKEet al. An outbreak of mumps with genetic strain variation in a highly vaccinated student population in Scotland. Epidemiol Infect (2017) 145:3219–25. doi: 10.1017/S0950268817002102
23
PatelLNArciuoloRJFuJGiancottiFRZuckerJRRakemanJLet al. Mumps Outbreak Among a Highly Vaccinated University Community-New York City, January-April 2014. Clin Infect Dis (2017) 64:408–12. doi: 10.1093/cid/ciw762
24
HavlickovaMLimberkovaRSmiskovaDHerrmannovaKJirincovaHNovakovaLet al. Mumps in the Czech Republic in 2013: Clinical Characteristics, Mumps Virus Genotyping, and Epidemiological Links. Cent Eur J Public Health (2016) 24:22–8. doi: 10.21101/cejph.a4512
25
NedeljkovicJKovacevic-JovanovicVMilosevicVSeguljevZPetrovicVMullerCPet al. A Mumps Outbreak in Vojvodina, Serbia, in 2012 Underlines the Need for Additional Vaccination Opportunities for Young Adults. PloS One (2015) 10:e0139815. doi: 10.1371/journal.pone.0139815
26
SaneJGoumaSKoopmansMde MelkerHSwaanCvan BinnendijkRet al. Epidemic of mumps among vaccinated persons, The Netherlands, 2009-2012. Emerg Infect Dis (2014) 20:643–8. doi: 10.3201/eid2004.131681
27
GillilandSMJenkinsAParkerLSomdachNPattamadilokSIncomserbPet al. Vaccine-related mumps infections in Thailand and the identification of a novel mutation in the mumps fusion protein. Biologicals (2013) 41:84–7. doi: 10.1016/j.biologicals.2012.09.007
28
BarskeyAESchulteCRosenJBHandschurEFRausch-PhungEDollMKet al. Mumps outbreak in Orthodox Jewish communities in the United States. N Engl J Med (2012) 367:1704–13. doi: 10.1056/NEJMoa1202865
29
RobertsCPorter-JonesGCrockerJHartJ. Mumps outbreak on the island of Anglesey, North Wales, December 2008-January 2009. Euro Surveill (2009) 14:19109. doi: 10.2807/ese.14.05.19109-en
30
CorteseMMJordanHTCurnsATQuinlanPAEnsKADenningPMet al. Mumps vaccine performance among university students during a mumps outbreak. Clin Infect Dis (2008) 46:1172–80. doi: 10.1086/529141
31
CastillaJGarcia CenozMBarricarteAIrisarriFNunez-CordobaJMBarricarteA. Mumps outbreak in Navarre region, Spain, 2006-2007. Euro Surveill (2007) 12:E070215.070211. doi: 10.2807/esw.12.07.03139-en
32
ZhengJZhouYWangHLiangX. The role of the China Experts Advisory Committee on Immunization Program. Vaccine (2010) 28 Suppl 1:A84–7. doi: 10.1016/j.vaccine.2010.02.039
33
DavisNFMcGuireBBMahonJASmythAEO’MalleyKJFitzpatrickJM. The increasing incidence of mumps orchitis: a comprehensive review. BJU Int (2010) 105:1060–5. doi: 10.1111/j.1464-410X.2009.09148.x
34
Centers for Disease Control and Prevention (CDC). Mumps epidemic–Iowa, 2006. MMWR Morb Mortal Wkly Rep (2006) 55:366–8.
35
TaeBSHamBKKimJHParkJYBaeJH. Clinical features of mumps orchitis in vaccinated postpubertal males: a single-center series of 62 patients. Korean J Urol (2012) 53:865–9. doi: 10.4111/kju.2012.53.12.865
36
A retrospective survey of the complications of mumps. J R Coll Gen Pract (1974) 24:552–6.
37
BartakV. Sperm count, morphology and motility after unilateral mumps orchitis. J Reprod Fertil (1973) 32:491–4. doi: 10.1530/jrf.0.0320491
38
CliffordVWadsleyJJennerBButteryJP. Mumps vaccine associated orchitis: Evidence supporting a potential immune-mediated mechanism. Vaccine (2010) 28:2671–3. doi: 10.1016/j.vaccine.2010.01.007
39
KandaTMochidaJTakadaSHoriYYamaguchiKTakahashiS. Case of mumps orchitis after vaccination. Int J Urol (2014) 21:426–8. doi: 10.1111/iju.12305
40
AbdelbakyAMChannappaDBIslamS. Unilateral epididymo-orchitis: a rare complication of MMR vaccine. Ann R Coll Surg Engl (2008) 90:336–7. doi: 10.1308/003588408X285694
41
SuzukiMTakizawaAFurutaAYanadaSIwamuroSTashiroK. A case of orchitis following vaccination with freeze-dried live attenuated mumps vaccine. Nihon Hinyokika Gakkai Zasshi (2002) 93:577–9. doi: 10.5980/jpnjurol1989.93.577
42
WhartonIPChaudhryAHFrenchME. A case of mumps epididymitis. Lancet (2006) 367:702. doi: 10.1016/S0140-6736(06)68274-3
43
TarantinoLGiorgioAde StefanoGFarellaN. Echo color Doppler findings in postpubertal mumps epididymo-orchitis. J Ultrasound Med (2001) 20:1189–95. doi: 10.7863/jum.2001.20.11.1189
44
ParkSJKimHCLimJWMoonSKAhnSE. Distribution of Epididymal Involvement in Mumps Epididymo-orchitis. J Ultrasound Med (2015) 34:1083–9. doi: 10.7863/ultra.34.6.1083
45
YangDMKimSHKimHNKangJHSeoTSHwangHYet al. Differential diagnosis of focal epididymal lesions with gray scale sonographic, color Doppler sonographic, and clinical features. J Ultrasound Med (2003) 22:135–42; quiz 143-134. doi: 10.7863/jum.2003.22.2.135
46
AdamopoulosDALawrenceDMVassilopoulosPContoyiannisPASwyerGI. Pituitary-testicular interrelationships in mumps orchitis and other viral infections. Br Med J (1978) 1:1177–80. doi: 10.1136/bmj.1.6121.1177
47
ChoiHIYangDMKimHCKimSWJeongHSMoonSKet al. Testicular atrophy after mumps orchitis: ultrasonographic findings. Ultrasonography (2020) 39:266–71. doi: 10.14366/usg.19097
48
BasekimCCKizilkayaEPekkafaliZBaykalKVKarsliAF. Mumps epididymo-orchitis: sonography and color Doppler sonographic findings. Abdom Imaging (2000) 25:322–5. doi: 10.1007/s002610000039
49
KrauseCHMolyneauxPJHo-YenDOMcIntyrePCarmanWFTempletonKE. Comparison of mumps-IgM ELISAs in acute infection. J Clin Virol (2007) 38:153–6. doi: 10.1016/j.jcv.2006.10.010
50
JalalHBahadurGKnowlesWJinLBrinkN. Mumps epididymo-orchitis with prolonged detection of virus in semen and the development of anti-sperm antibodies. J Med Virol (2004) 73:147–50. doi: 10.1002/jmv.10544
51
CasellaRLeibundgutBLehmannKGasserTC. Mumps orchitis: report of a mini-epidemic. J Urol (1997) 158:2158–61. doi: 10.1016/s0022-5347(01)68186-2
52
ErpenbachKH. Systemic treatment with interferon-alpha 2B: an effective method to prevent sterility after bilateral mumps orchitis. J Urol (1991) 146:54–6. doi: 10.1016/s0022-5347(17)37713-3
53
YeniyolCOSorgucSMinareciSAyderAR. Role of interferon-alpha-2B in prevention of testicular atrophy with unilateral mumps orchitis. Urology (2000) 55:931–3. doi: 10.1016/s0090-4295(00)00491-x
54
RothlinCVGhoshSZunigaEIOldstoneMBLemkeG. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell (2007) 131:1124–36. doi: 10.1016/j.cell.2007.10.034
55
FennerJEStarrRCornishALZhangJGMetcalfDSchreiberRDet al. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol (2006) 7:33–9. doi: 10.1038/ni1287
56
PiganisRADe WeerdNAGouldJASchindlerCWMansellANicholsonSEet al. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. J Biol Chem (2011) 286:33811–8. doi: 10.1074/jbc.M111.270207
57
BjorvatnB. Mumps virus recovered from testicles by fine-needle aspiration biopsy in cases of mumps orchitis. Scand J Infect Dis (1973) 5:3–5. doi: 10.3109/inf.1973.5.issue-1.02
58
WeisWBrownJHCusackSPaulsonJCSkehelJJWileyDC. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature (1988) 333:426–31. doi: 10.1038/333426a0
59
LiWHulswitRJGWidjajaIRajVSMcBrideRPengWet al. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein. Proc Natl Acad Sci U S A (2017) 114:E8508–17. doi: 10.1073/pnas.1712592114
60
TanCWHuan HorCHKwekSSTeeHKSamICGohELKet al. Cell surface alpha2,3-linked sialic acid facilitates Zika virus internalization. Emerg Microbes Infect (2019) 8:426–37. doi: 10.1080/22221751.2019.1590130
61
KubotaMTakeuchiKWatanabeSOhnoSMatsuokaRKohdaDet al. Trisaccharide containing alpha2,3-linked sialic acid is a receptor for mumps virus. Proc Natl Acad Sci U S A (2016) 113:11579–84. doi: 10.1073/pnas.1608383113
62
KubotaMOkabeINakakitaSIUeoAShiroganeYYanagiYet al. Disruption of the Dimer-Dimer Interaction of the Mumps Virus Attachment Protein Head Domain, Aided by an Anion Located at the Interface, Compromises Membrane Fusion Triggering. J Virol (2020) 94:e01732–19. doi: 10.1128/JVI.01732-19
63
WangFChenRJiangQWuHGongMLiuWet al. Roles of Sialic Acid, AXL, and MER Receptor Tyrosine Kinases in Mumps Virus Infection of Mouse Sertoli and Leydig Cells. Front Microbiol (2020) 11:1292. doi: 10.3389/fmicb.2020.01292
64
KubotaMMatsuokaRSuzukiTYonekuraKYanagiYHashiguchiT. Molecular Mechanism of the Flexible Glycan Receptor Recognition by Mumps Virus. J Virol (2019) 93:e00344–19. doi: 10.1128/JVI.00344-19
65
DengTChenQHanD. The roles of TAM receptor tyrosine kinases in the mammalian testis and immunoprivileged sites. Front Biosci (Landmark Ed) (2016) 21:316–27. doi: 10.2741/4390
66
BhattacharyyaSZagorskaALewEDShresthaBRothlinCVNaughtonJet al. Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors. Cell Host Microbe (2013) 14:136–47. doi: 10.1016/j.chom.2013.07.005
67
ShimojimaMTakadaAEbiharaHNeumannGFujiokaKIrimuraTet al. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol (2006) 80:10109–16. doi: 10.1128/JVI.01157-06
68
ShibataTHabielDMCoelhoALKunkelSLLukacsNWHogaboamCM. Axl receptor blockade ameliorates pulmonary pathology resulting from primary viral infection and viral exacerbation of asthma. J Immunol (2014) 192:3569–81. doi: 10.4049/jimmunol.1302766
69
RichardASShimBSKwonYCZhangROtsukaYSchmittKet al. AXL-dependent infection of human fetal endothelial cells distinguishes Zika virus from other pathogenic flaviviruses. Proc Natl Acad Sci U S A (2017) 114:2024–9. doi: 10.1073/pnas.1620558114
70
WangHChenYGeYMaPMaQMaJet al. Immunoexpression of Tyro 3 family receptors–Tyro 3, Axl, and Mer–and their ligand Gas6 in postnatal developing mouse testis. J Histochem Cytochem (2005) 53:1355–64. doi: 10.1369/jhc.5A6637.2005
71
PickarAXuPElsonAZengelJSauderCRubinSet al. Establishing a small animal model for evaluating protective immunity against mumps virus. PloS One (2017) 12:e0174444. doi: 10.1371/journal.pone.0174444
72
WangXXYingPDiaoFWangQYeDJiangCet al. Altered protein prenylation in Sertoli cells is associated with adult infertility resulting from childhood mumps infection. J Exp Med (2013) 210:1559–74. doi: 10.1084/jem.20121806
73
SadlerAJWilliamsBR. Interferon-inducible antiviral effectors. Nat Rev Immunol (2008) 8:559–68. doi: 10.1038/nri2314
74
ApariPde SousaJDMullerV. Why sexually transmitted infections tend to cause infertility: an evolutionary hypothesis. PloS Pathog (2014) 10:e1004111. doi: 10.1371/journal.ppat.1004111
75
KumarHKawaiTAkiraS. Pathogen recognition by the innate immune system. Int Rev Immunol (2011) 30:16–34. doi: 10.3109/08830185.2010.529976
76
GuazzoneVAJacoboPTheasMSLustigL. Cytokines and chemokines in testicular inflammation: A brief review. Microsc Res Tech (2009) 72:620–8. doi: 10.1002/jemt.20704
77
WilemanT. Autophagy as a defence against intracellular pathogens. Essays Biochem (2013) 55:153–63. doi: 10.1042/bse0550153
78
SpencerJVReligaPLehmannMH. Editorial: Cytokine-Mediated Organ Dysfunction and Tissue Damage Induced by Viruses. Front Immunol (2020) 11:2. doi: 10.3389/fimmu.2020.00002
79
DiemerTHalesDBWeidnerW. Immune-endocrine interactions and Leydig cell function: the role of cytokines. Andrologia (2003) 35:55–63. doi: 10.1046/j.1439-0272.2003.00537.x
80
SuhJHGongEYHongCYParkEAhnRSParkKSet al. Reduced testicular steroidogenesis in tumor necrosis factor-alpha knockout mice. J Steroid Biochem Mol Biol (2008) 112:117–21. doi: 10.1016/j.jsbmb.2008.09.003
81
WangFLiuWJiangQGongMChenRWuHet al. Lipopolysaccharide-induced testicular dysfunction and epididymitis in mice: a critical role of tumor necrosis factor alphadagger. Biol Reprod (2019) 100:849–61. doi: 10.1093/biolre/ioy235
82
TheasMSRivalCJarazo-DietrichSJacoboPGuazzoneVALustigL. Tumour necrosis factor-alpha released by testicular macrophages induces apoptosis of germ cells in autoimmune orchitis. Hum Reprod (2008) 23:1865–72. doi: 10.1093/humrep/den240
83
HughesEG. The effectiveness of ovulation induction and intrauterine insemination in the treatment of persistent infertility: a meta-analysis. Hum Reprod (1997) 12:1865–72. doi: 10.1093/humrep/12.9.1865
84
SiuMKLeeWMChengCY. The interplay of collagen IV, tumor necrosis factor-alpha, gelatinase B (matrix metalloprotease-9), and tissue inhibitor of metalloproteases-1 in the basal lamina regulates Sertoli cell-tight junction dynamics in the rat testis. Endocrinology (2003) 144:371–87. doi: 10.1210/en.2002-220786
85
SiemannDNStrangeDPMaharajPNShiPYVermaS. Zika Virus Infects Human Sertoli Cells and Modulates the Integrity of the In Vitro Blood-Testis Barrier Model. J Virol (2017) 91:e00623–17. doi: 10.1128/JVI.00623-17
86
YuleTDMontoyaGDRussellLDWilliamsTMTungKS. Autoantigenic germ cells exist outside the blood testis barrier. J Immunol (1988) 141:1161–7.
87
LiuMGuoSHibbertJMJainVSinghNWilsonNOet al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev (2011) 22:121–30. doi: 10.1016/j.cytogfr.2011.06.001
88
KrauseKKAzouzFShinOSKumarM. Understanding the Pathogenesis of Zika Virus Infection Using Animal Models. Immune Netw (2017) 17:287–97. doi: 10.4110/in.2017.17.5.287
89
LiNWangTHanD. Structural, cellular and molecular aspects of immune privilege in the testis. Front Immunol (2012) 3:152. doi: 10.3389/fimmu.2012.00152
Summary
Keywords
mumps, MuV, orchitis, testis, infertility
Citation
Wu H, Wang F, Tang D and Han D (2021) Mumps Orchitis: Clinical Aspects and Mechanisms. Front. Immunol. 12:582946. doi: 10.3389/fimmu.2021.582946
Received
11 August 2020
Accepted
04 March 2021
Published
18 March 2021
Volume
12 - 2021
Edited by
Michael H. Lehmann, Ludwig Maximilian University of Munich, Germany
Reviewed by
Nadine Krüger, Deutsches Primatenzentrum, Germany; Benhur Lee, Icahn School of Medicine at Mount Sinai, United States
Updates

Check for updates
Copyright
© 2021 Wu, Wang, Tang and Han.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Daishu Han, dshan@ibms.pumc.edu.cn
This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.